ClinicalTrials.gg
TerminatedNCT02693769Updated Dec 12, 2016

A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

A Phase 2/3 interventional study of fluticasone propionate/formoterol fumarate breath actuated inhaler and Indacaterol maleate / glycopyrronium bromide capsules in ACOS (Fixed Airflow Obstruction and Elevated Eosinophils), sponsored by Mundipharma Research Limited. Terminated at 1 site in Slovakia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-12-12.

Sponsored by Mundipharma Research Limited (part of Mundipharma) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Recruitment issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate whether fluticasone/formoterol Breath actuated inhaler is effective and well tolerated in the treatment of subjects with fixed airflow obstruction and elevated eosinophils.

Read the detailed description

The study is designed to provide efficacy and safety data for the use of fluticasone/formoterol Breath actuated inhaler in subjects with the characteristics of fixed airflow obstruction and elevated eosinophils. These patients have typically been excluded from previous Flutiform pMDI asthma and chronic obstructive pulmonary disease (COPD) trials; for example in asthma studies, patients with a smoking history of 10 pack years or more have been excluded, conversely in COPD studies patients with any prior history of asthma have been excluded. It is expected that the data from this study will provide a greater understanding of the effects of fluticasone/formoterol in this patient population

02

Conditions studied

  • ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)
03

In context

Lead sponsor

Mundipharma Research Limited is the lead sponsor of 36 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥ 40 years at Screening visit.
  2. Adequate :
  3. Diagnosis of fixed airflow obstruction with elevated eosinophils
  4. Subjects symptomatic at Visit 1 (CAT ≥10) despite currently receiving treatment with either LAMA or LABA monotherapy or LAMA + LABA as a combination inhaler or separate inhalers.
  5. Documented history of ≥ 1 moderate or severe respiratory disease exacerbations (requiring treatment with systemic and/or antibiotics and/or hospitalisation) in the previous year.
  6. Willing and able to replace current therapy for obstructive lung disease with study medication.
  7. Able to demonstrate correct use of a BAI, Breezehaler and pMDI.

Exclusion criteria

Exclusion Criteria:

  1. Respiratory disease exacerbation between 4 weeks prior to screening and Visit 3 (Randomisation).
  2. Previous treatment with ICS.
  3. Documented evidence of α1-antitrypsin deficiency.
  4. Other active respiratory disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease, cystic fibrosis, bronchiolitis obliterans.
  5. Use of long-term oxygen therapy (LTOT) at least 12 hours daily or mechanical ventilation.
  6. Chest X-ray or CT scans performed prior to screening which reveal evidence of abnormalities reflective of active disease not believed to be due to
  7. Evidence of uncontrolled cardiovascular disease.
  8. Evidence of clinically significant renal, hepatic, gastrointestinal, or psychiatric disease.
  9. Current or a previous history of cancer which has been in remission for \< 5 years (basal cell or squamous cell carcinoma of the skin which has been resected is not excluded).
  10. Clinically significant sleep apnoea requiring use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device.
  11. Participation in the acute phase of a pulmonary rehabilitation programme within 4 weeks prior to screening or during the study.
  12. Known or suspected history of drug or alcohol abuse in the last 2 years.
  13. Requiring treatment with any of the prohibited concomitant medications.
  14. Known or suspected or to any of the study drugs or .
  15. Received an drug within 30 days of the Screening.
  16. Received a systemic within 30 days of the Screening visit.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    fluticasone/formoterol BAI

    To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)

    Drug: fluticasone propionate/formoterol fumarate breath actuated inhaler · Drug: Indacaterol maleate / glycopyrronium bromide capsules

  • Active comparator
    Ultibro Breezhaler

    Ultibro Breezhaler 85/43 µg (1 puff o.d.)

    Drug: fluticasone propionate/formoterol fumarate breath actuated inhaler · Drug: Indacaterol maleate / glycopyrronium bromide capsules

Interventions

  • Drugfluticasone propionate/formoterol fumarate breath actuated inhaler
  • DrugIndacaterol maleate / glycopyrronium bromide capsules

    Drug pages: Indacaterol maleate · Glycopyrrolate

06

What researchers measure

Primary outcomes

  1. The efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.) versus Ultibro Breezhaler 85/43 µg (1 puff o.d.) in terms of the percentage of eosinophils in induced sputum

    Time frame: at Week 6 of each treatment

Secondary outcomes

  1. The efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.) versus Ultibro Breezhaler 85/43 µg (1 puff o.d.) in terms of the serum concentration of surfactant protein D (SPD)

    Time frame: at Week 6 of each treatment.

07

Study locations

1 site
  • JURMED, s.r.o.
    Košice, 040 01, Slovakia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Oct 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2016
First posted
Feb 29, 2016
Start
Jul 2016
Primary completionActual
Oct 2016
CompletionActual
Dec 2016
Last update
Dec 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02693769
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Jul 2016
Primary completion
Oct 2016
Completion
Dec 2016
Last update
Dec 12, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indacaterol maleate · Glycopyrrolate

Start the discussion